Evidence map›Paper›PMID 29986235›Full record

ArticleCancer epidemiology2018

Domperidone use and risk of primary liver cancer in the Clinical Practice Research Datalink.

Jake E Thistle, Jessica L Petrick, Baiyu Yang, Marie C Bradley, Barry I Graubard, Katherine A McGlynn

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jake E ThistleDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States.
Jessica L PetrickDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States.
Baiyu YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States; Stanford Cancer Institute, Stanford University, Palo Alto, CA, United States.
Marie C BradleyDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States.
Barry I GraubardDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States.
Katherine A McGlynnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States. Electronic address: mcglynnk@mail.nih.gov.
National Cancer Institute · USDivision of Cancer Epidemiology and Genetics

Funding

Clinical Genetic Studies of Familial and Hereditary Cancer SyndromesZIACP010144 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$111.8M
Intramural NIH HHS ZIA CP010144
6 · The paper itself

Abstract

backgroundPronounced sex-disparity in liver cancer suggests a role for hormones, one of which could be prolactin. Stimulation of prolactin production in mice via domperidone has been reported to decrease hepatocarcinogenesis, thus may have chemopreventive potential. To study the effect of domperidone in humans, a large medical records study was conducted.

methodsBased in the Clinical Practice Research Datalink, 1921 liver cancer cases and 7681 controls were identified. Conditional logistic regression was employed to estimate odds ratios (OR) and 95% confidence intervals (CI). Domperidone use was analyzed overall, and by number of prescriptions and cumulative dose.

resultsComparing ever- versus never-use, there was no association between domperidone and liver cancer among men (OR = 1.06, 95% CI: 0.76-1.48) or women (OR = 1.21, 95% CI: 0.82-1.76). Among men, there was no association with dose or number of prescriptions, while among women who received the highest doses (OR

conclusionDomperidone use was not associated with decreased liver cancer risk among all study participants. Among women, an increased risk at highest levels of exposure warrants further study.

Indexed as

Biomedical ResearchDatabases, FactualPractice Patterns, Physicians'AdultCase-Control StudiesDomperidoneDopamine AntagonistsFemaleHumansLiver NeoplasmsMaleMiddle AgedPrognosisRisk FactorsUnited StatesDomperidoneDopamine AntagonistsCPRDDomperidoneHormonesLiver cancerProlactinSex-discrepancySex-disparity

Identifiers

PMID29986235
PMCPMC7008444
OpenAlexW2872229626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.